Search

Your search keyword '"Symmans, W. Fraser"' showing total 10 results
Start Over Author "Symmans, W. Fraser" Journal npj breast cancer
10 results on '"Symmans, W. Fraser"'

3. Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.

Author

Lang, Julie E, Forero-Torres, Andres, Yee, Douglas, Yau, Christina, Wolf, Denise, Park, John, Parker, Barbara A, Chien, A Jo, Wallace, Anne M, Murthy, Rashmi, Albain, Kathy S, Ellis, Erin D, Beckwith, Heather, Haley, Barbara B, Elias, Anthony D, Boughey, Judy C, Yung, Rachel L, Isaacs, Claudine, Clark, Amy S, Han, Hyo S, Nanda, Rita, Khan, Qamar J, Edmiston, Kristen K, Stringer-Reasor, Erica, Price, Elissa, Joe, Bonnie, Liu, Minetta C, Brown-Swigart, Lamorna, Petricoin, Emanuel F, Wulfkuhle, Julia D, Buxton, Meredith, Clennell, Julia L, Sanil, Ashish, Berry, Scott, Asare, Smita M, Wilson, Amy, Hirst, Gillian L, Singhrao, Ruby, Asare, Adam L, Matthews, Jeffrey B, Melisko, Michelle, Perlmutter, Jane, Rugo, Hope S, Symmans, W Fraser, van 't Veer, Laura J, Hylton, Nola M, DeMichele, Angela M, Berry, Donald A, and Esserman, Laura J

Subjects
Clinical Research, Clinical Trials and Supportive Activities, Prevention, Breast Cancer, Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions
Abstract

HSP90 inhibitors destabilize oncoproteins associated with cell cycle, angiogenesis, RAS-MAPK activity, histone modification, kinases and growth factors. We evaluated the HSP90-inhibitor ganetespib in combination with standard chemotherapy in patients with high-risk early-stage breast cancer. I-SPY2 is a multicenter, phase II adaptively randomized neoadjuvant (NAC) clinical trial enrolling patients with stage II-III breast cancer with tumors 2.5 cm or larger on the basis of hormone receptors (HR), HER2 and Mammaprint status. Multiple novel investigational agents plus standard chemotherapy are evaluated in parallel for the primary endpoint of pathologic complete response (pCR). Patients with HER2-negative breast cancer were eligible for randomization to ganetespib from October 2014 to October 2015. Of 233 women included in the final analysis, 140 were randomized to the standard NAC control; 93 were randomized to receive 150 mg/m2 ganetespib every 3 weeks with weekly paclitaxel over 12 weeks, followed by AC. Arms were balanced for hormone receptor status (51-52% HR-positive). Ganetespib did not graduate in any of the biomarker signatures studied before reaching maximum enrollment. Final estimated pCR rates were 26% vs. 18% HER2-negative, 38% vs. 22% HR-negative/HER2-negative, and 15% vs. 14% HR-positive/HER2-negative for ganetespib vs control, respectively. The predicted probability of success in phase 3 testing was 47% HER2-negative, 72% HR-negative/HER2-negative, and 19% HR-positive/HER2-negative. Ganetespib added to standard therapy is unlikely to yield substantially higher pCR rates in HER2-negative breast cancer compared to standard NAC, and neither HSP90 pathway nor replicative stress expression markers predicted response. HSP90 inhibitors remain of limited clinical interest in breast cancer, potentially in other clinical settings such as HER2-positive disease or in combination with anti-PD1 neoadjuvant chemotherapy in triple negative breast cancer.Trial registration: www.clinicaltrials.gov/ct2/show/NCT01042379.

Published
2022

4. Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer

Author

Echeverria, Gloria V., Cai, Shirong, Tu, Yizheng, Shao, Jiansu, Powell, Emily, Redwood, Abena B., Jiang, Yan, McCoy, Aaron, Rinkenbaugh, Amanda L., Lau, Rosanna, Trevarton, Alexander J., Fu, Chunxiao, Gould, Rebekah, Ravenberg, Elizabeth E., Huo, Lei, Candelaria, Rosalind, Santiago, Lumarie, Adrada, Beatriz E., Lane, Deanna L., Rauch, Gaiane M., Yang, Wei T., White, Jason B., Chang, Jeffrey T., Moulder, Stacy L., Symmans, W. Fraser, Hilsenbeck, Susan G., and Piwnica-Worms, Helen

Published
2023
Full Text
View/download PDF

5. Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.

Author

Boughey, Judy C, Alvarado, Michael D, Lancaster, Rachael B, Symmans, W Fraser, Mukhtar, Rita, Wong, Jasmine M, Ewing, Cheryl A, Potter, David A, Tuttle, Todd M, Hieken, Tina J, Carter, Jodi M, Jakub, James W, Kaplan, Henry G, Buchanan, Claire L, Jaskowiak, Nora T, Sattar, Husain A, Mueller, Jeffrey, Nanda, Rita, Isaacs, Claudine J, Pohlmann, Paula R, Lynce, Filipa, Tousimis, Eleni A, Zeck, Jay C, Lee, M Catherine, Lang, Julie E, Mhawech-Fauceglia, Paulette, Rao, Roshni, Taback, Bret, Goodellas, Constantine, Chen, Margaret, Kalinsky, Kevin M, Hibshoosh, Hanina, Killelea, Brigid, Sanft, Tara, Hirst, Gillian L, Asare, Smita, Matthews, Jeffrey B, Perlmutter, Jane, Esserman, Laura J, and I-SPY2 Investigators

Subjects
I-SPY2 Investigators
Abstract

[This corrects the article DOI: 10.1038/s41523-018-0074-6.].

Published
2019

6. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness

Author

Metzger-Filho, Otto, Collier, Katharine, Asad, Sarah, Ansell, Peter J., Watson, Mark, Bae, Junu, Cherian, Mathew, O’Shaughnessy, Joyce, Untch, Michael, Rugo, Hope S., Huober, Jens B., Golshan, Mehra, Sikov, William M., von Minckwitz, Gunter, Rastogi, Priya, Li, Lang, Cheng, Lijun, Maag, David, Wolmark, Norman, Denkert, Carsten, Symmans, W. Fraser, Geyer, Jr., Charles E., Loibl, Sibylle, and Stover, Daniel G.

Published
2021
Full Text
View/download PDF

7. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

Author

Amgad, Mohamed, Stovgaard, Elisabeth Specht, Balslev, Eva, Thagaard, Jeppe, Chen, Weijie, Dudgeon, Sarah, Sharma, Ashish, Kerner, Jennifer K., Denkert, Carsten, Yuan, Yinyin, AbdulJabbar, Khalid, Wienert, Stephan, Savas, Peter, Voorwerk, Leonie, Beck, Andrew H., Madabhushi, Anant, Hartman, Johan, Sebastian, Manu M., Horlings, Hugo M., Hudeček, Jan, Ciompi, Francesco, Moore, David A., Singh, Rajendra, Roblin, Elvire, Balancin, Marcelo Luiz, Mathieu, Marie-Christine, Lennerz, Jochen K., Kirtani, Pawan, Chen, I-Chun, Braybrooke, Jeremy P., Pruneri, Giancarlo, Demaria, Sandra, Adams, Sylvia, Schnitt, Stuart J., Lakhani, Sunil R., Rojo, Federico, Comerma, Laura, Badve, Sunil S., Khojasteh, Mehrnoush, Symmans, W. Fraser, Sotiriou, Christos, Gonzalez-Ericsson, Paula, Pogue-Geile, Katherine L., Kim, Rim S., Rimm, David L., Viale, Giuseppe, Hewitt, Stephen M., Bartlett, John M. S., Penault-Llorca, Frédérique, Goel, Shom, Lien, Huang-Chun, Loibl, Sibylle, Kos, Zuzana, Loi, Sherene, Hanna, Matthew G., Michiels, Stefan, Kok, Marleen, Nielsen, Torsten O., Lazar, Alexander J., Bago-Horvath, Zsuzsanna, Kooreman, Loes F. S., van der Laak, Jeroen A. W. M., Saltz, Joel, Gallas, Brandon D., Kurkure, Uday, Barnes, Michael, Salgado, Roberto, and Cooper, Lee A. D.

Published
2020
Full Text
View/download PDF

8. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Author

Kos, Zuzana, Roblin, Elvire, Kim, Rim S., Michiels, Stefan, Gallas, Brandon D., Chen, Weijie, van de Vijver, Koen K., Goel, Shom, Adams, Sylvia, Demaria, Sandra, Viale, Giuseppe, Nielsen, Torsten O., Badve, Sunil S., Symmans, W. Fraser, Sotiriou, Christos, Rimm, David L., Hewitt, Stephen, Denkert, Carsten, Loibl, Sibylle, Luen, Stephen J., Bartlett, John M. S., Savas, Peter, Pruneri, Giancarlo, Dillon, Deborah A., Cheang, Maggie Chon U., Tutt, Andrew, Hall, Jacqueline A., Kok, Marleen, Horlings, Hugo M., Madabhushi, Anant, van der Laak, Jeroen, Ciompi, Francesco, Laenkholm, Anne-Vibeke, Bellolio, Enrique, Gruosso, Tina, Fox, Stephen B., Araya, Juan Carlos, Floris, Giuseppe, Hudeček, Jan, Voorwerk, Leonie, Beck, Andrew H., Kerner, Jen, Larsimont, Denis, Declercq, Sabine, Van den Eynden, Gert, Pusztai, Lajos, Ehinger, Anna, Yang, Wentao, AbdulJabbar, Khalid, Yuan, Yinyin, Singh, Rajendra, Hiley, Crispin, Bakir, Maise al, Lazar, Alexander J., Naber, Stephen, Wienert, Stephan, Castillo, Miluska, Curigliano, Giuseppe, Dieci, Maria-Vittoria, André, Fabrice, Swanton, Charles, Reis-Filho, Jorge, Sparano, Joseph, Balslev, Eva, Chen, I-Chun, Stovgaard, Elisabeth Ida Specht, Pogue-Geile, Katherine, Blenman, Kim R. M., Penault-Llorca, Frédérique, Schnitt, Stuart, Lakhani, Sunil R., Vincent-Salomon, Anne, Rojo, Federico, Braybrooke, Jeremy P., Hanna, Matthew G., Soler-Monsó, M. Teresa, Bethmann, Daniel, Castaneda, Carlos A., Willard-Gallo, Karen, Sharma, Ashish, Lien, Huang-Chun, Fineberg, Susan, Thagaard, Jeppe, Comerma, Laura, Gonzalez-Ericsson, Paula, Brogi, Edi, Loi, Sherene, Saltz, Joel, Klaushen, Frederick, Cooper, Lee, Amgad, Mohamed, Moore, David A., and Salgado, Roberto

Published
2020
Full Text
View/download PDF

9. Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint

Author

Boughey, Judy C., Alvarado, Michael D., Lancaster, Rachael B., Symmans, W. Fraser, Mukhtar, Rita, Wong, Jasmine M., Ewing, Cheryl A., Potter, David A., Tuttle, Todd M., Hieken, Tina J., Carter, Jodi M., Jakub, James W., Kaplan, Henry G., Buchanan, Claire L., Jaskowiak, Nora T., Sattar, Husain A., Mueller, Jeffrey, Nanda, Rita, Isaacs, Claudine J., Pohlmann, Paula R., Lynce, Filipa, Tousimis, Eleni A., Zeck, Jay C., Lee, M. Catherine, Lang, Julie E., Mhawech-Fauceglia, Paulette, Rao, Roshni, Taback, Bret, Goodellas, Constantine, Chen, Margaret, Kalinsky, Kevin M., Hibshoosh, Hanina, Killelea, Brigid, Sanft, Tara, Hirst, Gillian L., Asare, Smita, Matthews, Jeffrey B., Perlmutter, Jane, Esserman, Laura J., and I-SPY2 Investigators

Published
2019
Full Text
View/download PDF

10. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

Author

Laura Comerma, Marie-Christine Mathieu, Joel H. Saltz, Giancarlo Pruneri, Peter Savas, Shom Goel, Stephan Wienert, Paula I. Gonzalez-Ericsson, Lee Cooper, Sunil R. Lakhani, Stefan Michiels, Pawan Kirtani, Sarah N Dudgeon, Francesco Ciompi, Uday Kurkure, Manu M. Sebastian, Giuseppe Viale, Brandon D. Gallas, Mohamed Amgad, John M. S. Bartlett, Jan Hudecek, Torsten O. Nielsen, Elisabeth Specht Stovgaard, Huang-Chun Lien, Alexander J. Lazar, Johan Hartman, Yinyin Yuan, Rim S. Kim, Jeppe Thagaard, Ashish Sharma, Sylvia Adams, Matthew G. Hanna, Stephen M. Hewitt, Weijie Chen, David L. Rimm, Khalid AbdulJabbar, Sibylle Loibl, Jochen K. Lennerz, I-Chun Chen, Zsuzsanna Bago-Horvath, Mehrnoush Khojasteh, Frédérique Penault-Llorca, Katherine L. Pogue-Geile, Federico Rojo, Marcelo Luiz Balancin, David Moore, Stuart J. Schnitt, Roberto Salgado, Loes F. S. Kooreman, Sherene Loi, Jeremy P Braybrooke, Eva Balslev, Leonie Voorwerk, Sunil S. Badve, Elvire Roblin, Jennifer K. Kerner, Marleen Kok, Andrew H. Beck, Michael Barnes, Jeroen van der Laak, Carsten Denkert, W. Fraser Symmans, Zuzana Kos, Rajendra Singh, Anant Madabhushi, Christos Sotiriou, Sandra Demaria, Hugo M. Horlings, Department of Pathology, Herlev and Gentofte Hospital, The University of Sydney, Charité, Institute of Pathology, Translational Tumorpathology Unit, Division of Experimental Therapy, The Netherlands Cancer Institute NKI/AvL, Innovation North - Faculty of Information and Technology, Leeds Metropolitan University, Pathologie morphologique, Département de biologie et pathologie médicales [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), European Institute of Oncology [Milan] (ESMO), University of Southern Queensland (USQ), Instituto de Física Teórica UAM/CSIC (IFT), Universidad Autónoma de Madrid (UAM)-Consejo Superior de Investigaciones Científicas [Madrid] (CSIC), Institut Jules Bordet [Bruxelles], Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), Division of Pathology and Laboratory Medicine, Università degli Studi di Milano = University of Milan (UNIMI)-European Institute of Oncology [Milan] (ESMO), University of the Sunshine Coast (USC), Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), UNICANCER, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), German Breast Group (GBG), Breast Cancer Translational Research Laboratory, Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB)-Faculté de Médecine [Bruxelles] (ULB), Service de biostatistique et d'épidémiologie (SBE), Direction de la recherche clinique [Gustave Roussy], Institut Gustave Roussy (IGR), Oncostat (U1018 (Équipe 2)), Institut Gustave Roussy (IGR)-Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, The Netherlands Cancer Institute, The University of Texas M.D. Anderson Cancer Center [Houston], Medizinische Universität Wien = Medical University of Vienna, Computational Biomedicine Lab (CBL), University of Houston, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'anatomie pathologique, Universidad Autonoma de Madrid (UAM)-Consejo Superior de Investigaciones Científicas [Madrid] (CSIC), Università degli Studi di Milano [Milano] (UNIMI)-European Institute of Oncology [Milan] (ESMO), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de la Santé et de la Recherche Médicale (INSERM), German Breast Group, Medical University of Vienna, Department of Pathology, Amgad, Mohamed [0000-0001-7599-6162], Sharma, Ashish [0000-0002-1011-6504], Savas, Peter [0000-0001-5999-428X], Hudeček, Jan [0000-0003-1071-5686], Braybrooke, Jeremy P [0000-0003-1943-7360], Demaria, Sandra [0000-0003-4426-0499], Comerma, Laura [0000-0002-0249-4636], Badve, Sunil S [0000-0001-8861-9980], Symmans, W Fraser [0000-0002-1526-184X], Gonzalez-Ericsson, Paula [0000-0002-6292-6963], Rimm, David L [0000-0001-5820-4397], Loi, Sherene [0000-0001-6137-9171], Hanna, Matthew G [0000-0002-7536-1746], Lazar, Alexander J [0000-0002-6395-4499], Bago-Horvath, Zsuzsanna [0000-0002-8555-7806], van der Laak, Jeroen AWM [0000-0001-7982-0754], Gallas, Brandon D [0000-0001-7332-1620], Kurkure, Uday [0000-0002-8273-7334], Cooper, Lee AD [0000-0002-3504-4965], and Apollo - University of Cambridge Repository

Subjects
0301 basic medicine, Computer science, [SDV]Life Sciences [q-bio], Review Article, DIGITAL PATHOLOGY, Tumour biomarkers, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], Prognostic markers, 0302 clinical medicine, Breast cancer, Ecology,Evolution & Ethology, Visual scoring, Medicine and Health Sciences, Pharmacology (medical), Chemical Biology & High Throughput, Human Biology & Physiology, IN-SITU, Medicinsk bildbehandling, Genome Integrity & Repair, Sciences bio-médicales et agricoles, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, SOLID TUMORS, 3. Good health, Women's cancers Radboud Institute for Health Sciences [Radboudumc 17], Oncology, 030220 oncology & carcinogenesis, Tumour immunology, TILS, Tumor immunology, Genetics & Genomics, [SDV.CAN]Life Sciences [q-bio]/Cancer, Cancer imaging, lcsh:RC254-282, CLASSIFICATION, 03 medical and health sciences, Signalling & Oncogenes, STANDARDIZED METHOD, QUALITY-CONTROL, SDG 3 - Good Health and Well-being, BREAST-CANCER, Radiology, Nuclear Medicine and imaging, IMAGE-ANALYSIS, Computational & Systems Biology, Tumor-infiltrating lymphocytes, Digital pathology, Médecine pathologie humaine, Tumour Biology, Data science, Biomarker (cell), Cancérologie, Medical Image Processing, 030104 developmental biology, Workflow, T-CELLS
Abstract

Assessment of tumor-infiltrating lymphocytes (TILs) is increasingly recognized as an integral part of the prognostic workflow in triple-negative (TNBC) and HER2-positive breast cancer, as well as many other solid tumors. This recognition has come about thanks to standardized visual reporting guidelines, which helped to reduce inter-reader variability. Now, there are ripe opportunities to employ computational methods that extract spatio-morphologic predictive features, enabling computer-aided diagnostics. We detail the benefits of computational TILs assessment, the readiness of TILs scoring for computational assessment, and outline considerations for overcoming key barriers to clinical translation in this arena. Specifically, we discuss: 1. ensuring computational workflows closely capture visual guidelines and standards; 2. challenges and thoughts standards for assessment of algorithms including training, preanalytical, analytical, and clinical validation; 3. perspectives on how to realize the potential of machine learning models and to overcome the perceptual and practical limits of visual scoring., info:eu-repo/semantics/published

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results